IP Library Assignment 070239/0739
Patent Assignment
Reel/Frame 070239/0739

Security Interest

Recorded: 2025-02-17 Pages: 11
Assignor
REVANCE THERAPEUTICS, INC.
Executed: 2025-02-06
Assignee
JPMORGAN CHASE BANK, N.A.
3424 PEACHTREE ROAD NE, FLOOR 21, ATLANTA, GEORGIA, 30326
Covered Properties (53)
Injectable Botulinum Toxin Formulations
Application: 17/951,220 →
Publication: US US20240058628A1
Albumin-Free Botulinum Toxin Formulations
Application: 18/414,311 →
Publication: US US20240382571A1
Methods and Kits for Topical Application, Removal, and Inactivation of Therapeutic or Cosmetic Toxin Compositions
Application: 17/114,486 →
Publication: US US20210189326A1
Methods and Compositions for Treating Skin Conditions Associated With Vascular Hyper-reactivity
Application: 16/984,036 →
Publication: US US20220347275A1
Injectable Botulinum Toxin Formulations And Methods Of Use Thereof Having Long Duration Of Therapeutic Or Cosmetic Effect
Application: 17/472,525 →
Publication: US US20220062400A1
Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
Application: 17/135,938 →
Publication: US US20210252116A1
Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
Application: 17/234,690 →
Publication: US US20210308236A1
Methods of Treating or Preventing Migraine or Repetitive Occurrence of Common Migraine Headaches in a Subject Having Underlying Condition(s)
Application: 18/359,633 →
Publication: US US20240000906A1
Methods of Treating Cervical Dystonia in a Subject Having Underlying Condition(s)
Application: 18/455,179 →
Publication: US US20230390368A1
Methods of Treating a Spastic Disorder in a Subject Having Underlying Condition(s)
Application: 18/540,403 →
Publication: US US20240108700A1
Methods of Treating an Optic Disease in a Subject
Application: 18/521,777 →
Publication: US US20240100135A1
Transmucosal Botulinum Toxin Compositions, Kits, and Methods for Treating Bladder Disorders
Application: 18/973,057 →
Publication: US US20250332232A1
Methods of Treatment for Cervical Dystonia
Application: 17/547,211 →
Publication: US US20220096610A1
Injectable Botulinum Toxin Formulations and Methods of Use Thereof Having High Response Rate and Long Effect Duration
Application: 18/595,365 →
Publication: US US20250064905A1
Injectable Botulinum Toxin Methods for Treating Headaches
Application: 17/912,513 →
Publication: US US20230210963A1
Injectable Botulinum Toxin Methods for Treating Headaches
Application: 18/244,279 →
Publication: US 2024/0216486
Methods for Treating Cervical Dystonia
Application: 18/031,861 →
Publication: US US20240269246A1
Methods of and Compositions for Treatment of Upper Limb Spasticity
Application: 18/278,169 →
Publication: US US20250268996A1
Arginine Heteromers for Topical Administration
Patent: 8,815,954 →
Application: 11/617,551 →
Publication: US US20070265233A1
Arginine Heteromers for Topical Administration
Patent: 8,628,756 →
Application: 12/159,584 →
Publication: US US20090214452A1
Compositions and Methods for Treating Acne
Patent: 8,580,317 →
Application: 11/816,670 →
Publication: US US20100021571A1
Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins
Patent: 9,180,081 →
Application: 11/367,642 →
Publication: US US20070077259A1
Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins
Patent: 9,314,416 →
Application: 11/816,602 →
Publication: US US20090087457A1
Methods for Treating Pain by Topical Application and Transdermal Delivery of Botulinum Toxin
Application: 14/935,886 →
Publication: US US20160051646A1
Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins
Application: 16/140,288 →
Publication: US US20190247293A1
Compositions and Methods for Topical Diagnostic and Therapeutic Transport
Patent: 8,092,788 →
Application: 11/073,307 →
Publication: US US20050239705A1
Compositions and methods for topical application and transdermal delivery of botulinum toxins
Patent: 8,404,249 →
Application: 11/072,026 →
Publication: US US20050196414A1
Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins
Patent: 8,398,997 →
Application: 10/591,732 →
Publication: US US20080107690A1
Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins
Patent: 9,211,248 →
Application: 13/846,899 →
Publication: US US20130202636A1
Injectable Botulinum Toxin Formulations
Patent: 9,956,435 →
Application: 13/141,935 →
Publication: US US20110268765A1
Injectable Botulinum Toxin Formulations
Application: 16/656,115 →
Publication: US US20200215357A1
Albumin-Free Botulinum Toxin Formulations
Patent: 9,340,587 →
Application: 12/824,118 →
Publication: US US20100330123A1
Albumin-Free Botulinum Toxin Formulations
Application: 15/155,341 →
Publication: US US20160256532A1
Albumin-Free Botulinum Toxin Formulations
Application: 16/175,434 →
Publication: US US20190290740A1
Albumin-Free Botulinum Toxin Formulations
Application: 17/322,901 →
Publication: US US20210330766A1
Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin
Patent: 9,469,849 →
Application: 14/796,235 →
Publication: US US20150322419A1
Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin
Application: 16/700,728 →
Publication: US US20200277591A1
Antimicrobial Peptide, Compositions, and Methods of Use
Patent: 8,623,811 →
Application: 12/669,705 →
Publication: US US20100215591A1
Compositions and Methods for Safe Treatment of Rhinitis
Application: 15/155,551 →
Publication: US US20160250302A1
Composition for Therapeutic and Cosmetic Botulinum Toxin
Patent: 7,459,164 →
Application: 10/446,562 →
Publication: US US20040037853A1
Pharmaceutical Botulinum Toxin Compositions
Patent: 8,241,640 →
Application: 12/073,245 →
Publication: US US20110293663A1
Compositions, Methods and Devices for Preparing Less Painful Botulinum Toxin Formulations
Patent: 8,192,979 →
Application: 11/046,721 →
Publication: US US20060147471A1
Extended Length Botulinum Toxin Formulation for Human or Mammalian Use
Patent: 9,066,851 →
Application: 13/132,855 →
Publication: US US20120039862A1
Extended Length Botulinum Toxin Formulation for Human or Mammalian Use
Patent: 9,950,042 →
Application: 14/754,268 →
Publication: US US20150297684A1
Use of Botulinum Toxin for the Treatment of Cerebrovascular Disease, Renovascular and Retinovascular Circulatory Beds
Patent: 9,393,291 →
Application: 13/862,206 →
Publication: US US20140105883A1
Use of Botulinum Toxin for the Treatment of Cerebrovascular Disease, Renovascular and Retinovascular Circulatory Beds
Application: 14/931,329 →
Publication: US US20160051645A1
Topical Ocular Preparation of Botulinum Toxin for Use in Ocular Surface Disease
Patent: 9,901,627 →
Application: 14/803,574 →
Publication: US US20160015794A1
Topical Ocular Preparation of Botulinum Toxin for Use in Ocular Surface Disease
Application: 15/905,616 →
Publication: US US20200222512A9
Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
Patent: 8,926,991 →
Application: 11/447,984 →
Publication: US US20070009555A1
Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
Application: 14/852,990 →
Publication: US US20170252415A9
Treatment of sinusitis related chronic facial pain and headache with botulinum toxin injections
Patent: 8,691,769 →
Application: 10/793,964 →
Publication: US US20040247606A1
Transmucosal Botulinum Toxin Compositions, Kits, and Methods for Treating Bladder Disorders
Application: 16/643,320 →
Publication: US 2021/0162026
Methods of Using Botulinum Toxin for the Treatment of Hypervolemic Lip Deformity (Lip Ectropion)
Patent: 7,270,826 →
Application: 11/028,600 →
Publication: US US20050208075A1
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Dec 13, 2006
From: DAKE, MICHAEL D.; WAUGH, JACOB M.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 018628/0284 →
Assignment of Assignor's Interest Jan 17, 2007
From: WAUGH, JACOB M.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 018768/0065 →
Assignment of Assignor's Interest Oct 6, 2008
From: DAKE, MICHAEL D.; WAUGH, JACOB M.
To: REVANCE THERAPEUTICS, INC
Reel/Frame 021639/0144 →
Assignment of Assignor's Interest Oct 7, 2008
From: WAUGH, JACOB M.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 021662/0548 →
Assignment of Assignor's Interest Oct 7, 2008
From: WAUGH, JACOB M.; LEE, JAE HOON
To: REVANCE THERAPEUTICS, INC
Reel/Frame 021662/0606 →
Security Agreement May 29, 2009
From: REVANCE THERAPEUTICS, INC.
To: LEADER VENTURES, LLC
Reel/Frame 022756/0549 →
Security Agreement May 24, 2010
From: REVANCE THERAPEUTICS, INC.
To: LEADER VENTURES, LLC
Reel/Frame 024432/0187 →
Security Agreement Sep 22, 2011
From: REVANCE THERAPEUTICS, INC.
To: HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
Reel/Frame 026953/0726 →
Release of Security Interest Recorded at Reel/Frame 24432/321, 24432/284, 24432/317, 22432/187, and 22756/549 Oct 4, 2011
From: LEADER VENTURES, LLC
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 027015/0658 →
Release of Security Interest Sep 27, 2019
From: HERCULES CAPITAL, INC. (F/K/A HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 050565/0300 →
Assignment of Assignor's Interest Mar 16, 2022
From: RUEGG, CURTIS L.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 059281/0037 →
Change of Name Mar 17, 2022
From: ESSENTIA BIOSYSTEMS, INC.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 059435/0371 →
Employee Proprietary Information and Inventions Agreement Mar 17, 2022
From: WAUGH, JACOB
To: ESSENTIA BIOSYSTEMS, INC.
Reel/Frame 059435/0362 →
Security Interest Mar 18, 2022
From: REVANCE THERAPEUTICS, INC.
To: ATHYRIUM BUFFALO LP
Reel/Frame 059437/0654 →
Assignment of Assignor's Interest Mar 18, 2022
From: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 059436/0236 →
Assignment of Assignor's Interest Mar 18, 2022
From: BORODIC, GARY E.
To: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
Reel/Frame 059440/0061 →
Assignment of Assignor's Interest Jul 5, 2022
From: RUEGG, CURTIS L.; WAUGH, JACOB M.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 060399/0215 →
Assignment of Assignor's Interest Apr 17, 2023
From: RUBIO, ROMAN; NGUYEN-CLEARY, THAI; OH, CHAD
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 063350/0858 →
Assignment of Assignor's Interest Jul 27, 2023
From: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 064401/0001 →
Assignment of Assignor's Interest Jul 27, 2023
From: BORODIC, GARY E.
To: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
Reel/Frame 064401/0300 →
Assignment of Assignor's Interest Aug 24, 2023
From: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 064712/0088 →
Assignment of Assignor's Interest Aug 24, 2023
From: BORODIC, GARY E.
To: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
Reel/Frame 064712/0721 →
Assignment of Assignor's Interest Oct 23, 2023
From: BORODIC, GARY E.
To: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
Reel/Frame 065317/0816 →
Assignment of Assignor's Interest Oct 23, 2023
From: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 065317/0047 →
Assignment of Assignor's Interest Nov 29, 2023
From: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 065708/0926 →